08-12-2025 19:49 via medpagetoday.com

Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

(MedPage Today) -- ORLANDO--Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction chemotherapy, a phase II...

Adding Precision Immunotherapy Improved Sepsis Outcomes

Methadone Treatment Can Be Integrated Into Primary Care, Randomized Trial Shows

Swing District Republicans Brace for Political Fallout if Obamacare Subsidies Expire

Nordic People Say How to Beat the Winter Blues and Find Light in the Darkest Months

No, Those Aren’t Really ‘Holes’ in Kim Kardashian’s Brain

AI Isn't the Solution for Every Problem

Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

Apply Now: NLM Data Science & Informatics Scholars Program

Adding Procedures, Cutting the Paperwork

CDC Panel Targets Size of Childhood Vaccine Schedule, Safety of Aluminum Adjuvants

Experts Evaluate Aging and Hematologic Disease at ASH

IV Iron Tied to Lower Mortality Risk in Anemics Battling Infection

Fellow Nurses: Hep B Vaccine Recommendation for Newborns Was Dropped

Desktop versie

Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

Medical news